EN PL
Rheumatological aspects of pathogenesis and treatment of COVID-19 infection
 
Więcej
Ukryj
1
Clinic of Rheumatology, UMHAT St. Ivan Rilski University Hospital, Sofia, Bulgaria
 
 
Data publikacji online: 08-09-2021
 
 
Reumatologia 2021;(Konferencja Pacjent post-COVID-owy. Co zostaje, a co się zmienia? 1):261-264
 
SŁOWA KLUCZOWE
STRESZCZENIE
Contemporary rheumatology is a field dealing with the phenomena of autoimmune states and inflammation. Rheumatic diseases cover a wide spectrum of diseases of the musculoskeletal system, connective tissue and vessels. The occurrence of an immune, autoimmune and autoinflammatory response is often linked to different kinds of infections.
Which aspects of the coronavirus infection relate to rheumatological therapy and practice? In order to answer this question one needs to look at the pathogenesis of the SARS-CoV-2 infection. Antimalarial drugs may block antigen presentation of the viral peptides from antigen presenting cells, as they may alter the lysosomal proteases that mediate the viral entry in the cells and have demonstrated efficacy in improving the infection. Anti-IL-6 may interfere with cytokine storm in severe cases and use of tocilizumab has had good results in a small cohort. Baricitinib not only plays a role in inhibiting the synthesis of cytokines but it also has a function in suppressing receptor-mediated endocytosis.
The constantly new and tested concepts in the treatment of COVID testify to the growing knowledge about the virus, but also to the need for more targeted therapy. Treatment regimens have been developed for both patients with COVID-19 and those with symptomatic SARS-CoV infection and rheumatic disease. This article is an attempt to discuss the management of COVID-19 and coexisting rheumatic disease.
 
REFERENCJE (17)
1.
Klimpel GR. Immune defenses. In: Medical microbiology, 4th ed. NCBI Bookshelf; 1-21.
 
2.
Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Analysis 2020; 10: 102-108, DOI: 10.1016/j.jpha.2020.03.001.
 
3.
Lu R, Zhao X, Li J, et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565-574, DOI: 10.1016/S0140-6736(20)30251-8.
 
4.
Chen J, Subbarao K. The immunobiology of SARS. Annu Rev Immunol 2007; 25: 443-472, DOI: 10.1146/annurev.immunol.25.022106.141706.
 
5.
Zheng Y, Shang J, Yang C, et al. Lysosomal proteases are a determinant of coronavirus tropism. J Virol 2018; 92: e01504-e01518, DOI: 10.1128/JVI.01504-18.
 
6.
Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat Rev Microbiol 2009: 7: 439-450, DOI: 10.1038/nrmicro2147.
 
7.
Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. Sci Rep 2016; 6: 25359, DOI: 10.1038/srep25539.
 
8.
Ceribelli A, Motta F, De Santis M, et al. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun 2020; 109: 102442, DOI: 10.1016/j.jaut.2020.102442.
 
9.
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol 2017; 39: 529-539, DOI: 10.1007/s00281-017-0629-x.
 
10.
Yoshikawa T, Hill T, Li K, et al. Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol 2009; 83: 3039-3048, DOI: 10.1128/JVI.01792-08.
 
11.
Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7) (Released by National Health Commission & State Administration of Tradiitional Chinese Medicine on March 3, 2020).
 
12.
Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe of life-threatening cytokine release syndrome. Oncologist 2018; 23: 943-947, doi: 10.1634/theoncologist.2018-0028.
 
13.
Xh Xu M, Li T, Sun W, et al. Effective treatment of severe COVID-19 patients with Tocilizumab. ChinaXiv 2020; 20200300026.
 
14.
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet (London, England) 2020; 395: e30-e31, DOI: 10.1016/S0140-6736(20)30304-4.
 
15.
Yang Y, Peng F, Wang R, et al. The deadly coronaviruses: the 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China. J Autoimmun 2020; 109: 102434, DOI: 10.1016/j.jaut.2020.102434.
 
16.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020; 14: 72-73, DOI: 10.5582/bst.2020.01047.
 
17.
Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; 71:732-739, DOI: 10.1093/cid/ciaa237.
 
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
eISSN:2084-9834
ISSN:0034-6233
Journals System - logo
Scroll to top